IVF (INVO Fertility) reports Q1 2026 results on May 22 as one of the most financially distressed micro-caps on Nasdaq — the setup is less about short pressure and more about whether the company can show any sign of operational stabilisation.
The borrow market tells a more complicated story than the headline short interest. At just 0.74% of the free float, short interest is technically low and not the primary bear instrument here. But cost to borrow has jumped to nearly 70% annualised — up 30% in the past week alone — which is unusually punishing for a stock with so few shares shorted. That spike points to genuine scarcity among lenders willing to facilitate new positions. Availability has tightened from around 430% two weeks ago to 322% today, a meaningful directional move even if the absolute level still suggests borrowing is possible. The short score has climbed to 66.8, rising almost every session over the past two weeks from 62 to near 67, reflecting a market that is incrementally more bearish going into the number.
The fundamental picture leaves little room for the bulls to work with. Estimated revenue is $10.4 million, against a net loss of $5.4 million and an EBITDA loss of $2.3 million. The Z-score from ORTEX's stock scoring model is a deeply negative -6.03, and the F-score of zero signals almost no financial strength. The stock's composite score of 26.3 places it firmly in distressed territory — Momentum ranks at just 4.5 out of 100, driven by severe relative-strength deterioration across the 91-, 182-, and 365-day windows. The RSI14 has fallen to 25.9, well into oversold territory. The stock is down 32% over the past month and has lost 58% year-to-date. At $1.43, the market cap is approximately $2.6 million.
Institutional ownership is thin and concentrated. Mariner Managed Account Solutions holds 6.2% of shares — the largest single position — and entered the stock only in Q1 2026. Armistice Capital cut its stake by 46,000 shares in the same period. Insider activity is effectively absent; the most recent disclosed trade was a director selling just four shares in December 2025. Past earnings reactions have been volatile: the January 2026 print triggered an 18.9% single-day drop followed by a further 11% over five days, while November 2025 saw a 10.6% one-day decline and a 33% drawdown over the subsequent five sessions.
The May 22 print will test whether INVO Fertility can demonstrate any improvement in its cash burn trajectory — because in the absence of that, the financial distress signals embedded across every layer of the data have no obvious counterweight.
See the live data behind this article on ORTEX.
Open IVF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
